precision medicine

MELBOURNE, Australia, July 19, 2023 (GLOBE NEWSWIRE) -- GenEmbryomics, a medical genetics company with world leading intellectual property, today announced that it has retained WallachBeth Capital ("WallachBeth") as its financial advisor…

New York, May 26, 2023 (GLOBE NEWSWIRE) -- According to Market.us, the DNA Sequencing Market size is projected to surpass around USD 40.5 billion by 2032 and it is poised to reach a CAGR of 15.3% from 2023 to 2032. DNA sequencing…

<!-- Name:DistributionId Value:8788431 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8782008 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:2790 -->…

<!-- Name:DistributionId Value:8743891 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

BATON ROUGE, La., Dec. 06, 2022 (GLOBE NEWSWIRE) -- The Center for BioModular Multi-Scale Systems, or CBM2, was recently renewed for funding through the National Institutes of Health as a National Biotechnology Resource Center. CBM2’s…

SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell…

SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will…

Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with IND Filing on Track for 2H 2022 SOUTH…

SEATTLE, May 23, 2022 (GLOBE NEWSWIRE) -- adyn, the first to create a test designed to prevent birth control side effects, announced today the official launch of its flagship product, The Birth Control Test. While some side effects—like…